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1. Introduction 
Malignant hyperthermia (MH) is an inherited, pharmacogenetic disorder of the skeletal 
muscle, characterized by dangerous hypermetabolic state after anesthesia with 
succinylcholine and/or volatile halogenated anesthetic agents. MH may also be triggered in 
susceptible individuals by severe exercise in hot conditions, infections, neuroleptic drugs 
and overheating in infants1-4. 
MH produces rapid increase in body temperature (by as much as 1ºC in five minutes) and 
extreme acidosis. These are a result of acute loss of control of intracellular calcium levels and 
compensatory uncontrolled increases in skeletal muscle metabolism, which may progress to 
severe rhabdomyolysis. Critical worldwide attention to MH began in 1960 with the reports 
of Denborough and Lovell. They described MH in a young man who had a history of 
several deaths of relatives during anesthesia. He developed tachycardia, hot and sweaty 
skin, peripheral mottling and cyanosis during general anesthesia using halothane. After 
prompt symptomatic treatment, the episode was aborted5-6. The term malignant hyperthermia 
was first quoted by Wilson and colleagues in 19677. In this same year, Dantrolene  
Sodium, a hydantoin derivative (1-[5-(4-nitrophenyl)-2-furanyl]methylene]imino]-2,4-
imidazolidinedione), was first used because of its possible muscle-relaxing properties8. 
Shortly thereafter, dantrolene was shown to alleviate muscle spasticity effectively in 
animals9 and humans10. Later, it was shown that dantrolene uncoupled the excitation-
contraction process during skeletal muscle stimulation11. A few years later, an association 
between MH and porcine stress syndrome was proposed, providing an animal model for 
MH12-13. Because malignant hyperthermia was thought to result from continuous muscle 
contraction, perhaps through an abnormality in the excitation-contraction coupling 
mechanism, the compound was tested as a treatment for this condition14. 
In 1975, Harrison15 described the efficacy of dantrolene in preventing and treating porcine 
halothane induced-MH. By 1979 the U.S. Food and Drug Administration (FDA) approved 
dantrolene for use in humans with MH16. The effectiveness of dantrolene in human MH was 
then confirmed in a multihospital evaluation of dantrolene used to treat anesthetic-induced 
episodes17. More than four decades after its discovery, dantrolene remains the primary basis 
for successful MH therapy18. 
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In the late 1980s, Caffeine Halothane Contracture Test became the gold standard diagnostic 
test for MH and a variety of neuromuscular disorders associated with MH susceptibility. 
These disorders include central core disease, Duchenne muscular dystrophy, myotonia 
congenita, myotonic dystrophy, nonspecific myopathies, and King-Denborough syndrome19. 
During liver transplantation, some commonly employed anesthetic agents may trigger MH 
in susceptible patients. This occurrence, in such a complex scenario and with such delicate 
patients, can make anesthesia management even more challenging. Besides this, dantrolene 
is hepatotoxic, which can pose another injury risk to the graft20. 
2. General Information 
2.1 Incidence and prevalence 
In North America and Europe, the incidence of MH is currently estimated to be 1:15,000 
anesthetics for children and adolescents and 1:50,000–1:150,000 anesthetics for adults21-23. 
The prevalence for this syndrome in the general population is unknown because of lack of 
universal reporting, but although it may be as common as one in 200024. Malignant 
hyperthermia is more common in male patients25. The incidence and prevalence varies from 
country to country, based on differences in gene pools26-30.  
Although the incidence of reported episodes of MH has increased, the mortality rate from 
MH has declined. This may reflect a greater awareness of the syndrome, earlier diagnosis, 
and better therapy31. 
2.2 Risk factors 
Apparently, MH can exist regardless of race or gender although predominance in males and 
adolescents has been suggested25. Family history of fatal general anesthesia complications 
associated with the use of volatile agents or depolarizing muscle relaxants should make the 
anesthesiologist aware about the increased risk for MH.  
Patients with Duchenne muscular dystrophy, myotonia congenita, myotonic dystrophy, 
nonspecific myopathies, central core disease, King-Denborough, osteogenesis imperfecta and 
Schwartz-Jampel syndrome have an increased risk for MH syndrome19. Patients who 
develop masseter muscle rigidity (MMR) after administration of succinylcholine have an 
increased risk to develop MH in the next minutes, and 25% of these will show positive 
contracture tests to MH32-33.  
2.3 Pathophysiology 
Malignant hyperthermia is an inherited pharmacogenetic disorder of skeletal muscle, 
characterized by an increased calcium release from the skeletal muscle sarcoplasmic 
reticulum. A mutation in the ryanodine receptor (RyR) may be the main causative factor in 
many patients and families with MH34-35. The ryanodine receptor type 1 (RYR1) gene 
encodes the human skeletal muscle calcium release channel. RYR1 gene is responsible for 
the release of sarcoplasmic reticulum stores of calcium. In about 50% of MH susceptible 
families, there is a mutation in RYR136. The large variability among individuals may be 
explained by different genes causing MH in different families or by other predisposing 
factors being expressed differently in susceptible patients36. 
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The vast majority of patients susceptible to MH are asymptomatic in the absence of 
anesthesia. In humans, the defect only appears to be expressed significantly in skeletal 
muscle, although receptors are present in cardiac muscle37 and even in the liver38. Recently 
some authors suggested that RyR’s play an active role in the Ca2+ signaling of hepatocytes, 
creating local Ca2+ microdomains that enhance the responsiveness of neighboring Inositol 
Trisphosphate Receptors through Ca2+-positive feedback38. 
The exact mechanism by which different substances initiate a MH crisis has not been 
determined. It can be assumed, though, that a defect of intracellular Ca2+ homeostasis plays 
an important role. Susceptibility to MH is clearly based on an abnormal Ca2+ metabolism 
within the skeletal muscle, most probably caused by a defective Ca2+ release channel in the 
sarcoplasmic reticulum (SR), e.g. the ryanodine receptor which is the footplate protein 
seated between the dihydropyridine receptor and the sarcoplasmic reticulum39-41. The 
abnormal function of the ryanodine receptor of skeletal muscle in MH causes barely 
controlled concentration of calcium within the cell when it is not exposed to triggering 
agents42,43. The added loss of control of intracellular calcium on exposure to triggering 
agents or heat stress leads to marked metabolic stimulation within the cell to provide extra 
adenosine triphosphate to drive the calcium pumps that restore calcium to its reservoirs 
(e.g., sarcoplasmic reticulum, mitochondria, extracellular fluid)44. 
On a cellular level, magnesium acts as a physiological calcium inhibitor resulting in less-
intense calcium liberation from the sarcoplasmic reticulum. In normal resting muscle, 
cytosolic Mg2+ exerts a potent inhibitory influence on the SR Ca2+ release channel (ryanodine 
receptor, RyR1). Impaired Mg2+-regulation of RyR1 has been proposed as a causal factor in 
MH. The marked potentiation of SR Ca2+ release after a moderate reduction in cytosolic 
Mg2+ suggests that conditions which cause hypomagnesemia will increase the probability 
and possibly severity of an MH event. Conversely, maintenance of a normal or slightly 
increased cytosolic Mg2+ may reduce the probability of MH45. There is increasing evidence 
to suggest that defective Mg2+ regulation of RyR1 confers susceptibility to malignant 
hyperthermia. At the molecular level, interactions between critical RyR1 subdomains may 
explain the clustering of RyR1 mutations and associated effects on Mg2+ regulation46. 
MH is a syndrome caused by dysregulation of excitation-contraction (EC) coupling in 
skeletal muscle. The increased activity of pumps and exchangers trying to correct the 
increase in Ca2+ causes a need for ATP, which in turn produces heat. Thus, the end result is 
hyperthermia. The rigidity that is frequently seen during a fulminant MH episode is the 
result of the inability of the Ca2+ pumps and transporters to reduce the unbound 
myoplasmic Ca2+ below the contractile threshold44,47. Human malignant hyperthermia is a 
heterogeneous disorder, and the down-regulation of sodium channel subunit may be 
involved in the final common pathway through which mutations in any one of several 
proteins, including the ryanodine receptor, could render a person susceptible48. These 
changes would prolong the sodium current making the cell membrane depolarized for a 
longer time, increasing calcium release time period from the terminal cisternae. Patients 
expressing sodium channel abnormalities are at increased risk for muscle rigidity.  
2.4 Triggering agents 
All volatile anesthetics are triggers of malignant hyperthermia and must therefore be strictly 
avoided in malignant hyperthermia-susceptible patients. Furthermore, the depolarizing 
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muscle relaxant succinylcholine triggers the syndrome49. Isoflurane, desflurane and 
sevoflurane appear to be less potent triggers than halothane, but these agents can produce a 
more gradual or fast onset of MH50-56. The onset may be explosive if succinylcholine is 
used57. Local anesthetics, nondepolarizing muscle relaxants, barbiturates, benzodiazepines, 
droperidol, ketamine, nitrous oxide, opioids, and propofol are all safe drugs to administer in 
MH susceptible patients49.  
2.5 Clinical presentation 
The commonest clinical presentation of MH is a hypermetabolic state in a genetically 
susceptible individual in response to certain anesthetic agents, notably succinylcholine or 
halogenated volatile anesthetics. One of the earliest clinical signs is MMR after succinylcholine. 
In vitro muscle testing in patients who have developed this sign alone reveals that 28–50% are 
susceptible to MH. In the full-blown syndrome there is a rapid and sustained rise in body 
temperature, without shivering, either in the operating theatre or in the recovery room, in the 
absence of any obvious cause such as infection or a hot and humid environment. Tachycardia, 
cyanosis, generalized muscle rigidity, and cardiac arrhythmias are common clinical signs. 
There may be heating and rapid exhaustion of the soda-lime canisters. Acidosis is an early 
finding and there may also be hyperkalemia, hyperphosphatemia, and hypocalcemia from 
muscle-cell breakdown. Rhabdomyolysis is an important feature of the syndrome and is best 
demonstrated by measuring serum CK, which usually peaks on the second or third day after 
the reaction. Tenderness and swelling of muscles may develop, especially in the thighs. 
Myoglobinemia and myoglobinuria are common and renal failure may result from the 
rhabdomyolysis. Another complication is disseminated intravascular coagulation1.  
In less obvious cases, MH may present with one or any combination of the above clinical 
signs. The first indication of MH may be an unexplained cardiac arrest or cardiac 
arrhythmia. A rise in end-tidal CO2 is often the earliest indication of MH, and now that this 
is widely measured in clinical anesthesia MH may be picked up before the more florid signs 
develop. Previously apparently uncomplicated anesthesia with halothane and/or 
succinylcholine does not exclude the diagnosis of MH on a subsequent occasion. Factors 
such as the concentration of the anesthetic drugs used, the duration of the anesthesia, and 
the degree of MH susceptibility of the patient may explain why one anesthetic procedure is 
uneventful while another in the same patient is not1. 
When MH was first recognized as a complication of anesthesia the case-fatality rate was 
70%. Today, with the use of a specific drug for MH and the introduction of an in vitro 
muscle-contracture test59 to identify susceptibility to MH in individuals and their relatives, 
the case-fatality rate is only 5%1.  
3. Sodium dantrolene 
3.1 Pharmacokinetics 
Flewellen et al showed that after an intravenous dose of dantrolene, therapeutic levels were 
rapidly achieved and remain stable for around 5.5h. Subsequently, the dantrolene blood 
level slowly declined following first order kinetics with a half-life elimination of 12h. The 
mean residual blood dantrolene concentration present 20h after the last dose was  
1.7 mcg.ml-1 and, after 50h, that level was 0.3 mcg.ml-1 60. This same study evaluated 
neuromuscular effects of intravenous dantrolene in conscious patients and showed that 
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maximal depression of muscle twitch response (75% depression) and grip strength (42% 
depression) was accomplished after a cumulative dose of 2.4 mg.kg-1 body weight. Twenty 
four hours after such regimen, dantrolene levels were still high enough to cause strength 
reduction and a subjective weakness complaint only disappeared 48h after the last dose. On 
the other hand, spontaneous respiratory parameters (peak expiratory flow rate, vital 
capacity, end-tidal carbon dioxide and respiratory rate) did not change significantly during 
dantrolene administration. In children, the pharmacokinetic profile is similar, with a half-life 
of approximately 10 h61. 
Metabolism of dantrolene is achieved microsomally in the liver via oxidative and reductive 
pathways. Oxidation results in hydroxylation of the hydantoin ring to 5-hydroxydantrolene 
(5HD), while reduction of the nitro group of dantrolene leads to the formation of 
aminodantrolene, which is then acetylated to the reduced acetylated derivative (RAD) of 
dantrolene62.  
5HD is a metabolite with muscle relaxant effects. Compared with dantrolene sodium, it has 
a longer half-life (15,5h vs. 6h), but its activity is lower and its plasma levels are only 30-50% 
of its parent drug63. As a result, in healthy patients, 5HD can only be considered to play a 
minor role on the skeletal muscle relaxant properties of dantrolene therapy. The other 
metabolites have no relaxant effect. 
After an oral dose, 70% of dantrolene is absorbed. Twenty-five percent of the dose is 
excreted in urine, most of it as 5HD (79%) or RAD (17%); only 4% is excreted as unchanged 
drug62. Biliary excretion accounts for 45-50% of the oral dose administered64. Specific and 
detailed excretion studies after intravenous dantrolene are lacking. 
3.2 Pharmacodynamics 
Dantrolene is a unique muscle relaxant. Unlike neuromuscular blocking agents (site of 
action of which is at the nicotinic receptor of the neuromuscular junction) or the nonspecific 
relaxants (which modulate spinal cord synaptic reflexes), several studies have shown that 
dantrolene interferes with excitation-contraction coupling by reducing the concentration of 
myoplasmic calcium65-69. Consequently, muscle contraction is decreased without an effect on 
the action potential patterns of the neuromuscular junction70. 
However, the pathway by which dantrolene lowers myoplasmic Ca2+ is complex and still 
not fully understood. The ryanodine receptor of skeletal muscle (RyR1) has traditionally 
been thought to be the site of action of dantrolene66, and recent studies have located the 
molecular target of dantrolene to the area comprising amino acid residues 590 through 609 
of RyR171, strengthening that hypothesis. Some controversy was shed on that assumption 
when purified RYR1 was incorporated into an artificial planar lipid bilayer and no effect of 
dantrolene was detected in channel activity or pharmacology72. As a consequence, to date, 
we lack evidence of a direct action of dantrolene on purified RyR1 channels studied in lipid 
bilayers, even in the presence of calstabin 1, ATP, and activating concentrations of Ca2+, 
suggesting that dantrolene's main action is to alter key protein-protein interactions73. 
3.3 Side effects 
The two most frequently observed side-effects were muscle weakness in 22% and phlebitis 
in 10% of the patients.  
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Besides the intrinsic effect of dantrolene therapy, muscle weakness during MH may have a 
contribution of the muscle injury that is an integral part of the syndrome. Additionally, 
prolonged mechanical ventilation may, per se, exert deleterious effects on respiratory 
function. Although some authors objectively demonstrated strength reduction with 
clinically used doses of dantrolene60, no studies of pulmonary function have been performed 
in patients after MH crises, dantrolene therapy and intensive care management. As a result, 
careful attention with respiratory function is essential in these patients, especially during 
weaning of mechanical ventilation or in patients with borderline respiratory function, like 
those neuromuscular disorders. The clinicians treating an MH episode should request 
repeated measurement of creatine kinase until it returns to normal levels74. 
Because of its high alkalinity (pH = 9.6) after reconstitution, dantrolene should be 
preferentially administered through a large bore peripheral or central venous access to 
avoid local inflammatory phlebitis at the infusion site. Moreover, the sites of infusion should 
be frequently inspected for signs of extravasation and tissue necrosis. 
Besides these, the most commonly reported adverse effects can be grouped as of central 
(drowsiness, weakness, dizziness, malaise, fatigue, diplopia, dysarthria, seizures) and 
gastrointestinal (nausea, epigastric discomfort, diarrhea, constipation, abdominal pain) 
origin70. Gastrointesinal symptoms are more common with oral therapy75. Central nervous 
system symptoms may be worsened by sedatives and general anesthetics and it is not yet 
clear whether they are mediated by altered neuronal calcium homeostasis76.  
The side-effects were more commonly reported at the initiation of oral therapy and 
frequently disappeared with continued therapy and dose titration, although in 2.5% of 
patients they may be severe and persistent enough to warrant discontinuation of therapy64. 
Once the sarcoplasmic reticulum of heart muscle plays an essential role in the variable 
calcium release and uptake in excitation-contraction coupling, negative inotropic effects of 
dantrolene could be expected. The first studies to specifically address the effects of 
dantrolene on cardiovascular function evaluated healthy anesthetized dogs and showed no 
relevant effects on arterial pressure, central venous pressure, heart rate, coronary blood flow 
and cardiac output77-78. Later, other authors argumented that those results did not imply 
absence of effects on cardiovascular functions, since mechanisms of compensation may have 
had a role in maintaining the stability of the parameters investigated79. So, several authors 
began to study the effects of dantrolene in isolated animal cardiac muscle79-81, but these 
investigations resulted in divergent results. The human studies that addressed this issue did 
not show any relevant effects of therapeutic doses of dantrolene on cardiovascular function 
60, even in patients with poor cardiac function82. Whether this stability was due to complete 
absence of action of dantrolene on human myocardium or due to the action of compensating 
cardiovascular mechanisms is still a matter of debate. 
Another relevant cardiovascular issue has recently emerged in a two-decade registry 
analysis of the complications associated with dantrolene administration74. The authors 
found that the risk of any complication with dantrolene therapy increases with larger doses 
of dantrolene and fluid administration; on the other hand, this same study showed that the 
associated use of furosemide decreased that risk. Besides this, considering only the subset of 
patients with serious underlying disease or complex surgery (like liver transplant), there 
was a greater incidence of complications and these patients commonly presented more than 
one type of complication. 
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The interpretation of these findings has to be undertaken in light of the administration 
peculiarities of dantrolene. Each vial with 20 mg of dantrolene contains 3 g of mannitol (to 
improve liposolubility) and has to be reconstituted with 60 mL of sterile water. Thus, the 
results of the registry analysis would suggest that the mannitol content of dantrolene 
formulations, when combined with fluid administration, would further aggravate the fluid 
shifts related to the pathophysiology of MH and major surgeries, justifying the occurrence 
of complications like pulmonary edema. On the other hand, the careful use of furosemide to 
maintain urinary output and regulate intravascular volume status decreased these 
complications and has long been suggested by many authors. In this registry analysis, two 
of the 386 enrolled patients (0.5%) presented a decrease in cardiac output, but the authors 
did not sufficiently describe these cases to determine if it may have been the result of direct 
negative inotropism of dantrolene or due to other possible causes, like fluid overload. 
Liver transplantation is a very complex surgery and hepatorenal syndrome and cirrhotic 
cardiomyopathy are relatively common among liver transplant patients. Besides this, fluid 
management during liver transplantation, which is especially challenging because of 
massive bleeding and altered hemodynamics of cirrhotic patients, can become even more 
challenging with the occurrence of MH. As a result, dantrolene therapy may be especially 
prone to cardiovascular complications in this population. Because of these concerns, some 
authors suggest that documentation of cardiac filling pressures and cardiac output with 
continuous monitors such as echocardiography may improve management of critically ill 
subjects during MH treatment, although they were unable to demonstrate a reduction in 
dantrolene-associated complications with these measures. Furthermore, careful titration of 
the lowest effective dose regimen should always be sought. 
Although rarely encountered, chronic oral dantrolene therapy has been linked to different 
grades of hepatic damage, including fatal hepatitis in 0.1-0.3% of patients20,83. As a result, it 
received a black box warning for hepatotoxicity in 1976, early after its release in 197484. 
Despite these facts, a few authors suggest that other concomitant therapies may have had a 
role in that toxicity75-76. In addition, in vivo experiments in mice have not revealed any 
toxicity to hepatocytes85-86. In fact, recently, it was argued that dantrolene, due to its 
properties of restoring calcium homeostasis in scenarios of its disruption (like models of 
ischemia, hypoxia, seizure, trauma, anesthesia, and neurodegenerative diseases), may have 
cytoprotective effects in different tissue culture or animal models of diseases involving 
cytotoxicity induced by disruption of intracellular calcium homeostasis in pathogenesis87. 
Although the great majority of the studies agree that dantrolene may induce liver toxicity, 
the reports regarding intravenous short term dantrolene therapy are scarce, and most of the 
information is related to the oral long term dantrolene therapy in patients with spasticity 
disorders20. The only study that addressed the hepatic effects of intravenous dantrolene, 
found no significant differences in liver enzymes after its use, although it employed 
volunteers without any signs of MH60. In publications of oral therapy, some risk factors for 
dantrolene associated hepatitis have been identified like female sex, patients over the age of 
35 years and greater accumulated doses20,88. 
Although larger doses were identified as a risk factor, there is no agreement about the 
reactions involved in dantrolene hepatotoxicity and, until now, it is not known if the 
mechanism is dose-related or attributable to hypersensitivity (idiosyncratic reaction after a 
few doses)85,89-90. As described in the pathophysiology section, ryanodine receptors were 
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recently discovered in hepatocytes38. Whether dantrolene causes liver toxicity through these 
receptors or during its metabolism is unclear. 
Most of the patients with dantrolene hepatitis develop only mild and nonspecific symptoms 
(malaise, weakness, vomiting, fever, vomiting, jaundice)90, although fatal acute hepatic 
failure has been described93. Laboratory exams show different degrees of alterations in liver 
enzymes (alkaline phosphatase, AST, ALT) and bilirubin levels91. Histological findings of 
liver biopsies did not show a homogenous pattern, and multiple different descriptions were 
published (Table 1)20,88-90,92-95. If signs of hepatic injury develop during MH therapy, the 
treatment is mainly supportive and dantrolene should be stopped soon after control of the 
crisis, as dantrolene hepatitis is usually reversible after its withdrawal. 
In the two available reports of the use of dantrolene sodium during liver transplantation, 
there were alterations in postoperative laboratory exams, but the liver graft recovered 
uneventfully56,96. Actually, although dantrolene may pose an additive threat in the large set 
of perioperative injuries to the graft, abnormal symptoms and laboratory exams may be 
masked in the routine postoperative course of hepatic transplantation. Besides this, biopsies 
may not be of great help because histological patterns of dantrolene hepatitis do not greatly 
differ from those usually observed postoperatively in liver grafts. Consequently, prevention 
of dantrolene-induced hepatic injury is crucial. So, if malignant hyperthermia happens 
during liver transplantation, it seems prudent to, besides supportive treatment, use the 
lowest effective dose of dantrolene for the shortest time possible. 
Less commonly reported effects are acne-like rash, pruritus, urticaria, fever, hypersensitivity 
pleural effusion with pericarditis. 
4. Malignant hyperthermia in liver transplantation 
4.1 Preoperative evaluation and investigation of susceptibility 
Preoperative evaluation is crucial for all liver transplant candidates and, although 
involvement of multiple specialties like surgery, gastroenterology, cardiology, nephrology 
and endocrinology may be beneficial, it does not dispense with a judicious assessment by an 
anesthesiologist. Before planning anesthesia in a patient with known or suspected 
susceptibility to malignant hyperthermia, complete information about previous anesthetic 
procedures including complications or adverse events and other medical reports is 
needed97. Such evaluation is best accomplished and documented with the use of systematic 
formularies, where all collected data are registered and the anesthetic technique is 
individualized according to the risk factors for MH. The survey should include questions 
regarding muscular disorders, complications, deaths, unexplained high fever or dark-
colored urine after surgery. Symptoms like fever, cramps, muscular fatigue and weakness 
may suggest muscular disorders and susceptibility, but are overly common among 
candidates for liver transplantation and are of limited value.  
All common premedications like opioids, benzodiazepines, barbiturates, anticholinergics, 
and antihistamines are safe, but phenothiazines should not be administered. There is no 
need for preoperative use of dantrolene, but it must be immediately available in the 
operating room.  
It must be emphasized that uneventful previous anesthetics (even more than once) with 
MH-triggering agents do not preclude the occurrence of MH in future exposures56,98. 
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Some factors may have a role in attenuating MH crisis: pre-exposure hypothermia99, 
differential trigger potency for MH100 and variable genetic penetrance101. One of the 
described cases of MH during liver transplantation occurred in a patient who had previous 
uneventful general anesthetic31. 
4.2 Factors influencing the choice of anesthetic agents for liver transplantation and 
alternatives 
The choice of anesthetic agents for liver transplant surgery takes into account three key 
factors: maintenance of hemodynamic stability, lack of hepatic toxicity and pharmacokinetic 
profile102. 
Circulation of cirrhotic patients is hyperdynamic, showing low systemic vascular resistance 
and high cardiac output103-104. The use of betablockers for the prevention of variceal bleeding 
may render these patients bradycardic and hypotensive on arrival at the operating room. 
Besides this, large volume paracentesis, manipulation of major vessels, presence of surgical 
retractors, high propensity to massive bleeding and the reperfusion syndrome may all, per 
se, result in profound intraoperative hemodynamic changes. To further aggravate the 
scenario, it is widely known that most drugs used in anesthesia have negative effects on the 
cardiovascular system. As a result, judicious choice of anesthetic agents may help alleviate 
the tendency toward hemodynamic instability – the following choices are considered 
reasonable105. 
• Hypnotic agents for anesthetic induction: propofol in low doses (1.0 – 1.5 mg.kg-1)106; 
etomidate (0.2 – 0.3 mg.kg-1). Hypnotics are not triggers of MH. 
• Analgesic agents: fentanyl, sufentanil and remifentanil in continuous infusion are 
recommended; doses should be lower than usual, as the hepatic clearance is reduced. If 
remifentanil is used, postoperative hyperalgesia may be a concern107 and pain control 
regimens should receive special attention. Opioids are not triggers of MH. 
• Neuromuscular blocking agents: rapid sequence induction is recommended, since these 
patients commonly present with ascites108 and gastroparesis109. Succinylcholine is a 
common choice in these cases, although it should be avoided in patients susceptible to 
MH. Rocuronium is a safe alternative, although its effects may be prolonged because of 
its hepatic metabolism; furthermore, postoperatively, in case of graft dysfunction, 
extubation may be delayed110. For the maintenance of neuromuscular block, 
intermittent bolus or continuous infusion of intermediate-acting drugs independent of 
hepatic metabolism (atracurium or cisatracurium) are a good choice and should be 
guided by neuromuscular monitoring. 
• For maintenance of anesthesia during liver transplantation, halogenated inhalational 
agents (except halothane) or propofol in continuous infusion can be used. It has been 
shown that anesthetic requirements during liver transplantation are inversely 
proportional to the degree of hepatic dysfunction111, so careful titration of anesthetic 
doses with monitors like BIS© can minimize the negative cardiovascular effects of these 
drugs112. Isoflurane seems to be the most adequate halogenated agent, because it has 
few hemodynamic effects, lacks hepatotoxicity and protects hepatocytes from graft 
reperfusion injury113-114. On the other hand, isoflurane may be stronger trigger of MH 
than sevoflurane100.  
• In such a way, in MH susceptible patients, succinylcholine and halogenated inhalational 
anesthetics must be avoided and dantrolene must be available in the operating room.  
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Local anesthetics, nondepolarizing muscle relaxants, barbiturates, benzodiazepines, 
droperidol, ketamine, nitrous oxide, opioids, propofol and vasoactive drugs are all safe 
drugs to administer to these patients115. 
4.3 Suspected cases and confounding factors during liver transplantation 
MH syndrome exhibits a wide range of symptoms including tachycardia, progressive 
elevation of the exhaled CO2, arrhythmias, hyperthermia, profuse sweating, fever up to 
40ºC, cyanosis, poor skin perfusion and blood pressure instability31. The only physical sign 
typical of MH is muscular rigidity, although it may be hard to detect due to the limited 
access for physical evaluation. MMR may be observed upon anesthetic induction and is 
predictive of the syndrome32-33. 
However, tachycardia, arrhythmias, poor skin perfusion, blood pressure instability and 
other subtle manifestations of the initial phase of HM are commonly observed during liver 
transplantation, as it involves large volume paracentesis, manipulation of major vessels, 
massive bleeding and reperfusion syndrome116. Inadequate anesthetic depth and pyrogenic 
reaction can mimic some of those symptoms. 
Most of liver transplant patients are maintained normothermic with the aid of forced warm 
air mattresses. After the reperfusion, the graft begins to produce heat by its exothermic 
metabolic reactions and the addition of this new source of heat may lead to hyperthermia. 
However this temperature rise only begins lately in the course of the surgery, usually is 
minimized by turning off the mattresses and rarely exceeds 39ºC. Another potential source 
of confusion in the diagnosis of MH is the use of defective equipment for patient heating 
(leading to overheating and sweating) or poorly calibrated temperature monitors. 
Some situations can induce severe intraoperative Systemic Inflammatory Response 
Syndrome (SIRS) during liver transplantation, like bacteremia/sepsis, acute rejection and 
graft non-function. Although SIRS may show up with hyperthermia117, other MH symptoms 
like severe hypercapnia are not usually present in these cases. 
Hypercapnia may have several causes during liver transplantation, like intrinsic pulmonary 
diseases, accumulation of lung secretions in the airway, lung compression by retractors, 
inappropriate mechanical ventilation, exhaustion of soda lime and faulty carbon dioxide 
monitoring. However, after checking and solving all these issues, the maintenance of a 
progressive rise on end-tidal carbon dioxide becomes a strong indicator of malignant 
hyperthermia. 
To make diagnosis even problematic, most early laboratory manifestations of malignant 
hyperthermia, such as respiratory and lactic acidosis and hyperkalemia, are also commonly 
observed in anesthesia for liver transplantation. The reasons for respiratory acidosis were 
described above. Lactic acidosis frequently results from the combination of tissue 
hypoperfusion and decreased hepatic clearance of lactate during the anhepatic phase. 
Hyperkalemia during liver transplantation may have several reasons, like poor baseline 
renal function, large and rapid transfusion of red cells and high-potassium content of 
preservation solutions. Nonetheless, mixed venous oxygen saturation (SvO2) may have a 
lower value when MH is suspected. Due to severe increase in cellular oxygen consumption, 
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the SvO2 of patients with MH is usually low. Such low values are not usually seen in liver 
transplantation, since cirrhotic patients generally have systemic shunts and a hyperdynamic 
circulation, yielding high values of SvO2118. 
4.4 Intraoperative differential diagnosis 
Several disorders share similarities with MH and may be confused with the syndrome. 
Neuroleptic malignant syndrome is characterized by hyperthermia, acidosis, 
hyperkalemia and myoglobinuria following use of a wide variety of neuroleptics, 
especially haloperidol. Patients taking mono-amino-oxidase inhibitors who receive 
meperidine may present with hyperthermia, acidosis and an increase in creatine kinase 
concentration, what may become fatal. Other conditions that may resemble the MH 
situation include – but are not limited to – : iatrogenic overheating, thyroid storm in 
thyrotoxicosis, hypothalamic lesions, heat illness, pheochromocytoma, and intrathecal 
injection of high osmolar contrast agents, cocaine or ecstasy overdose, hypoxic 
encephalopathy and sudden cardiac arrest in a patient with occult myopathy119. None of 
these disorders, however, is frequent in liver transplant patients. 
4.5 Investigation of suspected cases 
Investigation of susceptibility should begin upon clinical suspicion during preoperative 
evaluation. 
Creatine kinase (CPK) dosage during rest has been suggested as a component of a clinical 
grading scale to predict malignant hyperthermia susceptibility for patients with positive 
family history; increased resting values could suggest myopathy and MH susceptibility120. 
The use of this test is not recommended for the general population as it would yield an 
unacceptably high rate of false positive results. Cirrhotic patients habitually have reduced 
muscle mass and decreased exercise-tolerance, thus high CPK results in patients with 
positive family history are suggestive. 
Caffeine-Halothane Contracture Test (CHCT) is considered the gold standard for the 
diagnosis of MH. This test, which uses a small piece of live muscle from biopsy, assesses 
the muscular contractility in response to increasing concentrations of halothane and 
caffeine exposure. It has a 97% sensitivity and 78% specificity121. Even in typical cases, 
CHCT is beneficial to guide the necessity of investigation of relatives. MH is inherited in 
an autosomal dominant pattern, meaning that if one of the parents has the disease, the 
risk of his or her passing it down to sons or daughters is 50 per cent122. Muscle biopsy for 
CHCT should be avoided in patients whose weight is less than 20 kg, patients under 
chronic dantrolene or calcium channel blocker therapy and in the first three months after 
a MH crisis, because muscle lesion may still be present123. A muscle sample is removed 
from the vastus lateralis or medialis or rectus abdominis. As the tests have to be finished up 
to five hours after its collection, patients have to be transported to specialized MH centers. 
The procedure is performed under general or regional anesthesia, obviously avoiding 
potentially trigerring agents and keeping dantrolene immediately available123. CHCT is 
indicated in patients preoperatively deemed at risk for MH, postoperatively in patients 
with a typical MH crisis during liver transplantation and the relatives of the patients with 
a positive CHCT.  
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4.6 Management and treatment of MH during anesthesia for liver transplantation  
4.6.1 Intraoperatively 
Protocols for MH treatment prioritize four mainstays: immediate discontinuation of trigger 
agents, administration of antidote (sodium dantrolene), life support measures and 
prevention of complications124-125.  
In the acute phase of MH the following steps are recommended: 
1. Immediate discontinuation of triggering agents: some MH crisis may be attenuated or 
aborted with discontinuation of triggering agents. When MH or MMR is identified soon 
after induction, postponement of the surgery is commonly recommended119. In liver 
transplant surgery, however, the decision to postpone the procedure is very tough. The 
anesthesiologist is faced with a patient who has a delicate clinical status that may be 
worsened either by a MH crisis or by returning to the waiting list. All the medical team 
should be involved in this sentence.  
2. Call for help: initiation of measures to treat MH, including the laborious process of 
dantrolene dilution, may be troublesome for one only anesthesiologist. Consequently 
the presence of another health professional (preferably an anesthesiologist) may be of 
valuable help. 
3. Adjust ventilation: increase minute ventilation to lower EtCO2 and use 100% oxygen. 
There is no need to change the breathing circuit or the soda lime canister126. 
4. Administer the antidote: Dantrolene is the drug of choice in treatment of malignant 
hyperthermia127. The contents of each bottle should be diluted in 60 mL of sterile water 
rather than solutions such as 5 percent dextrose in water or bicarbonate because the 
extra molecules in solution lead to a salting-out effect with greater difficulty in 
dissolving dantrolene. If it does not dissolve immediately, producing a clear yellow to 
yellow-orange color, it should be heated under tap water or autoclaved for a few 
minutes128. In a dire emergency, it should be administered through a blood filter 
without concern for crystals. Dantrolene should be preferentially administered through 
a large bore peripheral or central venous access to avoid local inflammatory phlebitis at 
the infusion site.  
General dosing regimens recommend an initial bolus of 2.5 mg.kg-1, which can be 
repeated every 5 minutes until normalization of the hypermetabolic state and the 
disappearance of all MH symptoms. After this initial control, a continuous intravenous 
dantrolene infusion at 10 mg.kg-1.day-1 should be given for at least 24 h after initial 
successful therapy76.  
Although this is the classical regimen, it may be excessive and deleterious in liver 
transplantation patients. In this scenario, although the diseased liver is removed and a 
new liver graft is transplanted, the transplanted liver unavoidably sustains warm, cold, 
and reperfusion injuries during graft procurement and transplantation129. Dantrolene 
sodium is considered hepatotoxic and the hepatic effects of dantrolene on such liver 
allografts are unknown. As a result, it seems prudent to use the lowest effective dose for 
the shortest time possible. 
There are two published case reports of MH in liver transplantation, with identical 
clinical presentation and successful treatment with lower than usual dantrolene 
doses56,96. One of the reports used a 1 mg.kg-1 dose intraoperatively, followed by 1 
mg.kg-1 every eight hours for 36 hours; the authors observed signs of hepatic 
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dysfunction 9 days after the transplant, which was attributed to dantrolene and had 
spontaneous resolution56. In the other report, the same intraoperative dose was used  
(1 mg.kg-1) and no maintenance dose was used; in this case, no signs of liver graft 
dysfunction were observed96.  
Therefore, to minimize the risks of graft toxicity by dantrolene, it seems prudent to 
adopt intraoperative doses of 1 mg.kg-1, which may be repeated every 30 minutes until 
control of symptoms. Next, the patient should be closely observed for MH 
recrudescences; if these occur, a regimen of 1 mg.kg-1 every eight hours for 36 hours 
should be instituted. 
5. Begin active cooling measures: hypothermic blanket under and over the patient (if 
possible); cold isotonic saline for intravenous infusion and for gastric, vesical, peritoneal 
or rectal irrigation, as appropriate; ice packs to groin, axilla, and neck. To avoid 
hypothermia, cooling measures should be stopped when temperature decreases to 
38ºC130. 
6. Treatment of metabolic acidosis: drugs like sodium bicarbonate or THAM are usually 
required to keep pH within the acceptable range132. 
7. Treatment of hyperkalemia: pH should be raised with the aid of hyperventilation 
and/or sodium bicarbonate or THAM. Glucose-insulin infusions may be helpful. In the 
past, authors contraindicated the use of Calcium Chloride during MH because they 
feared worsening of the crisis131, on the other hand, today, it seems reasonable to use it 
to antagonize hyperkalemia-induced electrocardiographic changes132. 
8. Treatment of cardiac arrhythmias: the control of hyperkalemia and acidosis usually 
alleviates this problem. When they persist, the treatment should be guided according to 
internationally accepted protocols, like Advanced Cardiac Life Support©. Calcium 
blockers should not be used along with dantrolene, since hyperkalemia (sometimes 
culminating in cardiovascular collapse) has been described in animals with such a drug 
combination132.  
9. Optimize urine output: an output greater than 2 mL.kg-1 should be instituted with the 
use of fluids and diuretics, like furosemide and mannitol. Such measure prevents the 
development of renal injury secondary to rhabdomyolysis and helps the control of 
hyperkalemia124. 
10. Follow blood gases, electrolytes, creatine kinase, coagulation profile and urine 
myoglobin. 
11. Call for specialized center: several countries have toll-free phone numbers for MH 
centers. As MH is a rare disorder, few anesthesiologists are fully used to its treatment 
when it happens. With such call, one may receive valuable instructions. 
4.6.2 Postoperatively 
1. Observation and monitoring: as much as 25% of patients with MH will present a 
recrudescence of the syndrome several hours after its initial control133. As a result, 
authors recommend observation in Intensive Care Units for 24-72 hours 
postoperatively32. Samples for blood gases, electrolytes, creatine kinase, coagulation 
profile and blood and urine myoglobin should be collected every 6-12 hours76,131. 
Habitually, immediate postoperative tests show evidence of hepatic injury (increased 
liver enzymes) and coagulopathy. Such profile mainly results of the ischemic injury to 
the graft and is self-limited when the graft begins to work. When MH occurs during 
liver transplantation, it is not clear if dantrolene can make these abnormalities more 
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severe nor if it can contribute to graft dysfunction. Irrespective of these uncertainties, 
the postoperative management is similar: graft function should be closely followed, 
dantrolene doses should be minimized to control symptoms and supportive treatment 
should be instituted. Liver biopsy has a limited value in this scenario, since the 
histopathological patterns of dantrolene hepatotoxicity are comparable to the ones 
usually observed in liver transplantation and the treatment choice does not change. If 
severe graft dysfunction ensues despite minimal use of dantrolene, retransplantation 
should be considered.  
2. Postoperative dantrolene therapy: in liver transplant patients, after initial control of 
MH, dantrolene should be reserved for recrudescences (to minimize liver toxicity). The 
dosage regimen is recommended 1 mg.kg-1 every eight hours for 36 hours. 
3. Mechanical ventilation weaning: one of the most reported side-effects of dantrolene is 
muscle weakness, which may persist up to 24-48h after the last dose. Although some 
authors objectively demonstrated strength reduction with clinically used doses of 
dantrolene60, no studies of pulmonary function have been performed in patients after 
MH crises, dantrolene therapy and intensive care management. As a result, careful 
attention with respiratory function is essential in these patients, especially during 
weaning of mechanical ventilation or in patients with borderline respiratory function, 
like those neuromuscular disorders. 
4. Refer patient and family to MH Testing Center for contracture or DNA testing134-135. 
4.7 Perioperative management of liver transplantation candidates susceptible to 
malignant hyperthermia 
Patients at risk for MH may be identified based on data collected on preoperative 
evaluation, like clinical symptoms, presence of muscular disease and personal and family 
history of previous anesthetics (see preoperative evaluation section). CHCT is indicated in 
patients preoperatively deemed at risk for MH, postoperatively in patients with a typical 
MH crisis during liver transplantation and the relatives of the patients with a positive 
CHCT. Anesthesia for liver transplantation in patients with some risk factors for MH must 
be free of succinylcholine and halogenated inhalational agents. Additionally, dantrolene 
must be immediately available in the operating room. Besides this, some precautions have to 
be taken with the anesthesia machine. Avoidance of succinylcholine is an easy to deal issue. 
However, avoidance of vapor anesthetics is more challenging because anesthesia machines 
retain anesthetic vapors long after discontinuation. Instructions for clearing residual 
anesthetic gases include removal or disabling of vaporizers, flushing the machine with a 
fresh gas flow rate more than 10 L.min-1 using the ventilator for at least 20 min, and 
replacement of the fresh gas outlet hose, carbon dioxide absorbent, and anesthesia circuit. 
The goal is to decrease the residual anesthetic vapor concentration within the breathing 
circuit. These precautions represent the standard of care for the management of MH-
susceptible patients. These instructions for purging anesthetic gases were derived from 
studies designed to optimize gas clearance in older generation machines. Modern anesthesia 
workstations are more complex and contain more gas absorbing materials. The current 
guidelines are inadequate to prepare newer generation workstations, which require more 
time for purging anesthetic gases, autoclaving or replacement of parts, and modifications to 
the gas delivery system. As a result, institutions must develop protocols that individualize 
their own new generation anesthesia machines136. 
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Malignant hyperthermia is an inherited pharmacogenetic disorder of the skeletal muscle. It 
can be triggered by any halogenated inhalational agent or by succinylcholine. A mutation on 
the Ryanodine Receptor (RyR) may be the main causative factor, resulting in a defect of 
intracellular Ca2+ homeostasis. Besides muscle tissue, RyR’s are present in hepatocytes. 
Dantrolene is the only available treatment for MH and is a unique muscle relaxant that 
interferes with excitation-contraction coupling by reducing the concentration of myoplasmic 
calcium. This drug seems to be hepatotoxic, although the exact mechanism is unclear. 
Preoperative evaluation of liver transplant candidates by anesthesiologist is critical to 
identify patients at risk or susceptible to MH. There is a significant overlap between the MH 
clinical manifestations and the usual physiological behavior during liver transplantation, 
and early clinical diagnosis is a challenge. Sustained and progressive increases in EtCO2, 
despite checking and solving other possible causes, should raise suspicion of MH. 
Treatment should be aimed towards discontinuing triggering agents, administering the 
antidote and instituting supportive measures. Due to its possible hepatotoxicity, dantrolene 
should be used in doses lower than usual and for shorter periods of time. 
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